Bausch + Lomb announced an exclusive licensing agreement with Stada Arzneimittel and its development partner Xbrane Biopharma to develop and commercialize a biosimilar candidate to Lucentis in the U.S. and Canada.
The Lucentis (ranibizumab, Genentech) biosimilar is currently known as Xlucane. Xbrane and Stada will finalize development of the biosimilar, with Xbrane providing the commercial supply. After regulatory approval, Bausch + Lomb will undertake marketing, sales and commercialization of the product in the U.S. and Canada.
“Through this agreement with Stada and Xbrane, we will be
Uncategorized